SBIR/STTR Research Award

SALMONELLA MUTAGENICITY STUDY USING MULTIPLE DATABASES

Award identifier 060e34aab0cd82995d73e1d0c5241fbe9683b3973bb834183b3ef1a1d74fc989Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$87,580

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MULTICASE, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
VR7GK47SL858
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The mutagenicity of chemicals is believed to be an important feature towards the chemical causing cancer. At present, there is a limited amount of feasible computational models to estimate the mutagenic potential of new substances. We proposed to develop a new method for predicting mutagenicity by a combination approach of multiple genicity databases using the M-CASE software. The databases will be separated by different Salmonella typhimurium strains and by test conditions. A similar condition model has previously been developed for carcinogenicity as a guide in this mutagenicity study In addition, we have developed a single preliminary database to elucidate the potential of this project. This proposal will outline the carcinogenicity results and estimate the improvement possible for mutagenicity. In addition, we have developed a single preliminary database to elucidate the potential of this project. For the Phase I project, we wish to develop four to six of these mutagenicity modules with the goal of producing a total of 24 mutagenicity databases after Phase II funding. PROPOSED COMMERCIAL APPLICATIONS: The need for pre-emptive determination of mutagenic compounds is immense to the regulatory, environmental and pharmaceutical and pharmaceutical industries. In the regulatory bodies such as the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA), the ability to quickly and accurately assess a new chemical for potential harmful activity to human or the environment is critical to an effective screening process. The incorporation of this multiple level analysis for mutagenicity as a tool to assist regulators will increase productivity and accuracy of their work. In the pharmaceutical industry, the ability to locate pharmacophores early in the stages of research and development will potentially save massive amounts of time and money for the company. This preventative assessment of mutagenicity of new chemical is clearly important for companies in the environment industry.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2001–2002). Reported award amounts total $725,825. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.